From: A randomized phase III study of short-course radiotherapy combined with Temozolomide in elderly patients with newly diagnosed glioblastoma; Japan clinical oncology group study JCOG1910 (AgedGlio-PIII)
α/β value
Clinical trials
Radiation dose/fractions
1.2
3.0
5.6
10.0
Conventional radiotherapy
60 Gy/30 fr
60.0
Perry et al., 2017 [10], CE.6
40 Gy/15 fr
48.4
45.4
43.6
42.3
Roa et al., 2015 [13]
25 Gy/5 fr
40.0
34.9
31.3
Malmström et al., 2012 [12], Nordic study
34 Gy/10 fr
48.9
43.5
40.3
38.0
